Navigation Links
NewLink Initiates Pivotal Phase 3 Clinical Trial of HyperAcute(R)-Pancreas Immunotherapy for Resected Pancreatic Cancer
Date:5/27/2010

ed into the human body. The response is strong enough to destroy transplanted cells and tissues within hours. NewLink's HyperAcute immunotherapy exploits this hyperacute antigen-antibody response to educate a patient's immune system to attack and destroy the patient's own unmodified cancer cells.

The company's HyperAcute products are composed of irradiated, allogeneic (off the shelf), whole cancer cells that have been genetically modified to add alpha-Gal residues to cell-surface lipids and proteins. The alpha-Gal epitopes function as a molecular adjuvant, effectively harnessing the xenotransplant rejection mechanism.

About HyperAcute-Pancreas Immunotherapy

HyperAcute-Pancreas immunotherapy consists of two equal cell doses of allogeneic pancreatic cancer cell lines engineered to express the murine alpha-Gal gene. Although cells making up naturally occurring pancreatic tumors in patients do not express alpha-Gal, they share other molecules including new tumor-specific and tumor -associated antigens, with the genetically altered pancreatic cancer cells introduced by the immunotherapy. Those similarities are believed to allow the antibodies and immune cells targeting alpha-Gal to redirect their attack and destroy patient's own tumor cells.

About Pancreatic Cancer

Cancer of the pancreas is the fourth leading cause of cancer death in the United States, killing more than 35,000 Americans in 2009. The disease is divided into two broad subtypes based on histological classification: pancreatic endocrine tumors are diagnosed in 5 percent of cases, and pancreatic adenocarcinoma accounts for the remaining 95 percent. Incidence and age-adjusted mortality rates of pancreatic adenocarcinoma are nearly equal, meaning the disease is almost universally fatal. Pancreatic cancer is
'/>"/>

SOURCE NewLink Genetics
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related biology technology :

1. NewLink Genetics Corporation Closes $7.5 Million Financing
2. NewLink Genetics to Present Phase 2 Data on HyperAcute(R)-Pancreas Immunotherapy at the American Society of Clinical Oncology Annual Meeting
3. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
4. Dawson James Securities Initiates Research Coverage on CryoCor, Inc. (Nasdaq: CRYO) with a Strong Buy Rating and $6.00 Target Price
5. Spectrum Pharmaceuticals Initiates Second Registrational Phase 3 Clinical Trial for EOquin(R) in Patients With Non-Invasive Bladder Cancer
6. XTL Biopharmaceuticals Initiates Phase IIb Clinical Trial of Bicifadine for the Treatment of Diabetic Neuropathic Pain
7. Nventa Initiates HspE7 Phase 1 Cervical Dysplasia Trial
8. Cytochroma initiates Phase I/II clinical trial of CTAP101 Capsules for vitamin D insufficiency in chronic kidney disease
9. Arena Pharmaceuticals Initiates Second and Third Pivotal Trials Evaluating Lorcaserin for the Treatment of Obesity
10. GeneNews initiates patient sample accrual for validation studies of colon cancer blood test
11. Human Genome Sciences Initiates Second Randomized Phase 2 Trial of HGS-ETR1 in Combination With Chemotherapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2013)... Cambridge Semantics was one of just 22 companies ... Capitol Hill, hosted by The Data Transparency ... showcase how innovative data management applications can address the requirements ... , Originally introduced in 2011 by Committee Chairman ... Warner (D-VA ), the DATA Act is designed to ...
(Date:5/22/2013)... The Conference Forum announced ... Advance Clinical Trials conference taking place on September 19-20 ... , Disruptive thinkers from Novartis, Pfizer, Eli Lilly, ... approaches to reduce expensive infrastructure, engage patients and generate ... be big, or novel, or it must change the ...
(Date:5/22/2013)... , May 22, 2013   Oligomerix, Inc. ... of disease modifying therapeutics for Alzheimer,s disease (AD) ... of its Series B financing, which includes both ... that would represent approximately $2.8M in new investments ... investors supported the raise. Funding ...
(Date:5/22/2013)...  Empire Genomics announced today it has acquired ... genomic biomarker from Cornell University for use in ... in diagnosing and determining treatment for patients with ... prostate cancer (NEPC) is a lethal variant of ... but more commonly arises after hormonal therapy for ...
Breaking Biology Technology:Cambridge Semantics Underscores Need for Smart Data during “Data Demonstration Day” on Capitol Hill 2Disruptive Innovation Hits Clinical Trials, Dedicated Event Launches 2Oligomerix, Inc. Completes Series B Financing 2Oligomerix, Inc. Completes Series B Financing 3Empire Genomics Licenses Novel DNA Biomarker for Use in Diagnosing and Creating a Companion Diagnostic Test for Neuroendocrine Prostate Cancer 2
... 2011  The 2011 National Ergonomics Conference and Exposition (ErgoExpo) held ... again the largest annual gathering of ergonomics decision makers and ... and by the last few hours of the show, the ... had already renewed and new exhibitors had signed up for ...
... ReportsnReports adds new market research report , Aseptic Packaging ... the $3.5 billion US aseptic packaging industry. It presents ... 2010, and forecasts for 2015 and 2020 by product ... and pouches, cartons, cups, glass bottles) and market (e.g., ...
... Renowned experts in cord blood collection, processing and transplantation ... its commitment as a worldwide industry leader in developing and ... treating patients.  Dr. Wise Young ... Medical Director.  He will serve in a voluntary ...
Cached Biology Technology:2011 ErgoExpo Attendees' Choice Award Winners Announced During Sold Out Expo; Exhibitor Renewal for 2012 Hits 96% and Counting 22011 ErgoExpo Attendees' Choice Award Winners Announced During Sold Out Expo; Exhibitor Renewal for 2012 Hits 96% and Counting 3ReportsnReports - Aseptic Packaging to 2015 2ReportsnReports - Aseptic Packaging to 2015 3StemCyte Adds World Class Talent to its North America and Global Operations 2StemCyte Adds World Class Talent to its North America and Global Operations 3
(Date:5/20/2013)... resistant to the antibiotic colistin are also commonly ... body, according to a study in mBio ... Society for Microbiology. Cross-resistance to colistin and host ... body against bacterial attack, could mean that patients ... with a crippled immune response. Colistin is a ...
(Date:5/20/2013)... Foundation (NSF) planning grant will help establish the Center ... of the University of Illinois at Urbana-Champaign and Worcester ... be devoted to research in drying moist, porous materials ... paper products; chemical products; textiles; and biopharmaceuticals," said Hao ... and human nutrition and the Illinois site director. , ...
(Date:5/19/2013)... that can grow using hydrogen gas as its sole ... of carbon. Researchers at the University of Massachusetts, ... of the American Society for Microbiology. , "This represents ... says Amit Kumar, a researcher on the study who, ... Lab Group at the university. , Under the leadership ...
Breaking Biology News(10 mins):Resistance to last-line antibiotic makes bacteria resistant to immune system 2Resistance to last-line antibiotic makes bacteria resistant to immune system 3NSF approves planning grant for Center for Advanced Research in Drying 2
... Researchers at the University of Kentucky Markey Cancer Center ... insight into the genetic mechanisms underlying Huntington,s disease and ... (or TNRs) in DNA. , The research, performed ... of toxicology and biochemistry and the Madeline James & ...
... a time when federal and private funds for biomedical research ... in the fight against muscle diseases by announcing grants to ... "Federal support for the type of work ... current economic climate. Simply put, without the support of MDA, ...
... [Brown University] Global warming may exact a toll ... shows that one key constituent of marshes may be ... salt marshes. Despite the stresses associated with global warming, ... a graduate student and salt marsh expert at Brown ...
Cached Biology News:Researchers gain insight into mechanism underlying Huntington's 2'Show me the money!' MDA greenlights grants 2'Show me the money!' MDA greenlights grants 3Climate change may spell demise of key salt marsh constituent 2
...
MBS 384 well satellite block unit with height adjusting heated lid, 384 well block holds 1 x 0.04 ml 384 well plate...
Wellpro 96 an automated liquid handling system for 96-well plates that quickly and accurately prepares large quantities of serial dilutions. The Wellpro also performs plate to plate transfers using ...
Multidrop DW is a high-speed automated dispenser for Deep Well plates, 1.1 ml test tubes and 96-well plates. Designed for accuracy and precision, the Multidrop DW dispenses up to eight different reag...
Biology Products: